Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives $14.90 Average Target Price from Analysts

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have received an average rating of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $14.90.

A number of research analysts have weighed in on the stock. HC Wainwright lifted their price target on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. B. Riley Financial lifted their price target on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, December 31st. Truist Financial assumed coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, March 5th. They set a “buy” rating and a $18.00 price target on the stock. Jefferies Financial Group lifted their price target on shares of Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a research report on Wednesday, December 31st. Finally, Wall Street Zen cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th.

Vanda Pharmaceuticals Price Performance

Vanda Pharmaceuticals stock opened at $7.22 on Friday. The company has a market cap of $426.76 million, a price-to-earnings ratio of -1.94 and a beta of 0.71. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.38 and a current ratio of 2.39. Vanda Pharmaceuticals has a 1 year low of $3.81 and a 1 year high of $9.94. The firm has a 50 day moving average price of $7.57 and a 200 day moving average price of $6.58.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). The business had revenue of $57.22 million for the quarter, compared to analyst estimates of $59.28 million. Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%. Sell-side analysts predict that Vanda Pharmaceuticals will post -1.12 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Mihael Hristos Polymeropoulos sold 156,235 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $8.17, for a total transaction of $1,276,439.95. Following the sale, the chief executive officer owned 2,704,496 shares in the company, valued at $22,095,732.32. This trade represents a 5.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Gunther Birznieks sold 42,431 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total transaction of $350,904.37. Following the transaction, the senior vice president directly owned 494,197 shares in the company, valued at approximately $4,087,009.19. The trade was a 7.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 314,342 shares of company stock valued at $2,583,985 over the last three months. Company insiders own 10.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Torren Management LLC purchased a new position in shares of Vanda Pharmaceuticals in the fourth quarter valued at $25,000. Russell Investments Group Ltd. boosted its stake in shares of Vanda Pharmaceuticals by 456.6% in the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 5,328 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in shares of Vanda Pharmaceuticals by 3,010.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 10,055 shares during the period. Jain Global LLC purchased a new position in shares of Vanda Pharmaceuticals in the fourth quarter valued at $94,000. Finally, Quarry LP purchased a new position in shares of Vanda Pharmaceuticals in the third quarter valued at $53,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.